Source link : https://newshealth.biz/health-news/exceptional-use-recommendation-for-nuclear-emergency-drug/
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an exceptional circumstances marketing authorization for Imreplys. The drug — active ingredient sargramostim and manufactured by Partner Therapeutics Ltd — is intended to treat people with hematopoietic acute radiation syndrome (H-ARS) following acute exposure to myelosuppressive doses of radiation. H-ARS […]
The post Exceptional Use Recommendation for Nuclear Emergency Drug first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-20 13:15:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8